Purpose: To assess the efficacy of a protocol involving the discontinuation of the GnRH analogue at the mid-phase of ovarian stimulation for IVF in patients with
INTRODUCTION
The introduction of gonadotropin-releasing hormone analogues (GnRH-a) into assisted reproduction technique (ART) protocols some 12 years ago greatly contributed to the success of modern IVF treatment. These medications induce pituitary desensitization, thereby suppressing premature endogenous LH surges, reducing cancellation rates, improving the overall number of oocytes retrieved, and improving implantation rates (1, 2) . However, other reports indicate that GnRH-a may be responsible for some direct adverse effects on ovarian function, especially steroidogenesis (3, 4) . Oocyte quality was also found to be dependent on GnRH-a concentration in vitro so that high levels of GnRH-a inhibited fertilization and lower levels actually enhanced fertilization (5, 6) . It might be concluded, therefore, that ovarian responsiveness to gonadotropin stimulation could actually improve if the GnRH-a effect was rescinded during stimulation.
The recovery of pituitary sensitivity after discontinuation of GnRH-a is variable, depending on patients age, dose and mode of administration, and the degree of ovarian stimulation, especially estradiol levels. Although some patients were able to release LH after stopping GnRH-a in as little as 3 days, and primate data demonstrate that the refractory phase does not last more than 6 days (7), the average pituitary recovery time after cessation of nasally administered GnRH-a was found to be 7-10 days (8, 9) . Discontinuing GnRH-a in mid-stimulation phase would allow this additional time for enhanced stimulation while the pituitary was still refractory. The aim of this study was to examine whether discontinuation of the GnRH-a during controlled ovarian hyperstimulation for IVF would result in an augmented ovarian response, without significantly increasing the cancellation rate, in the same patients.
MATERIAL AND METHODS
Thirty-six patients enrolled in our in vitro fertilization (IVF) program were included in this study. The average age of the patients was 34.7 ± 6.9 years in the range of 30-42 years. The indication for IVF included male factor infertility (n = 20), tubal factor infertility (n = 13) and unexplained infertility (n = 3). The median number of previous IVF cycles was 3, with a 95% confidence interval (CI) of 1-5 cycles. When more than one cycle of treatment was done, the last cycle was chosen for evaluation. Cycle day 3 FSH levels were all below 15 IU/L (range: 4.5-13.2, mean: 8.9 ± 4.2 IU/L). The FSH levels were accepted only if simultaneous serum estradiol levels were <200 pmol/L. These patients were selected after undergoing an initial cycle with the standard Nafarelin-hMG protocol. This entails nasal administration of Nafarelin acetate (Synarel, Delpharm, France) 200 µg per inhalation thrice daily from the mid-luteal phase of a natural cycle, through menses and the stimulation phase until the administration of human Chorionic Gonadotropin (hCG, Chorigon, Teva, Petach Tikva, Israel) 36-40 h before oocyte pick-up. Human Menopausal Gonadotropin (hMG, Pergonal, Teva, Petach Tikva, Israel) was administered starting on the fifth day of menses, with a starting dose of 3 ampoules per day (225 IU) for 4 days and continuing with individually adjusted doses until follicles of 20 mm in diameter were identified by transvaginal ultrasound, when 10000 IU (intramuscular) hCG would be administered. Oocyte pick-up was achieved by transvaginal puncture under general anesthesia. Oocytes were denuded and only mature oocytes (Metaphase II) were injected with spermatozoa, using the intra cytoplasmic sperm injection (ICSI) technique. ICSI was performed in all cycles, in an effort to maximize the number of available embryos for transfer, even when semen analysis did not warrant micromanipulation. Fertilizations were identified after 24 h and cleavage of embryos was assessed after 48 h. Embryo morphology was graded using a standard system including size and uniformity of blastomeres and the degree of fragmentation, as outlined by Veeck (10) and Plachot et al. (11) , whereby Grade I represents the best morphological status. Grade I: blastomeres of equal size, no cytoplasmic fragments; Grade II: blastomeres of equal size, with minor cytoplasmic fragments or blebs (10-20% of perivitelline space occupied); Grade III: blastomeres of distinctly unequal size, moderate degree of fragmentation (20-50% of perivitelline space occupied); Grade IV: unequal sized blasomeres, more than 50% of embryo surface fragmented, degenerative appearance. Grade I embryos were awarded a score of 1, the next best were awarded a score of 1.5, and so on until Grade IV embryos (the poorest) were given a score of 4.
These 36 patients were selected after reponding poorly in the initial standard cycle. The poor response was defined as either obtaining 5 oocytes or less, or obtaining embryos of poor quality-mean (arithmetical mean of the embryos replaced) score 2.5 or worsejudged by at least two experienced observers (DS and OB or RR or both). The subsequent cycle was similar in every respect to the original standard cycle including the dose and timing of the Nafarelin administration and dose and timing of the hMG. In the "N-stop" cycle, Nafarelin was discontinued after 5 days of hMG administration, and hMG was continued until follicles and estradiol warranted hCG administration.
Parameters measured included days of stimulation, dose of hMG, peak estradiol (day of hCG), the number of oocytes obtained, rate of cleavage of embryos, morphology scores of replaced embryos, the number of cycles cancelled due to premature LH rise, and pregnancy rates. The ovarian response was also assessed by expressing the number of oocytes obtained and the peak estradiol level as a function of the amount of hMG administered. Scoring of embryo morphology in the subsequent cycle was done using the same criteria and scoring system, and the observer was blinded to the medical protocol used in the same cycle.
STATISTICS
The results of the study were analyzed by paired t test: pairs of data in each parameter category were compared between the standard cycle and the N-stop cycle for each patient. The mean change in each category was calculated by expressing the change (delta value) in that parameter from the standard cycle to the N-stop cycle as a fraction of the value in the standard cycle, using the following equation:
value in N-stop cycle − value in standard cycle value in standard cycle .
The sum of values for each category (mean delta value) expressed the overall change in that parameter between the two protocols.
RESULTS
In the standard protocol, 1 cycle was cancelled of 36, whereas 3 cycles of 36 (8.3%) were cancelled in the N-stop protocol, due to a premature LH rise before hCG was administered. The average length of the stimulation phase was slightly longer in the standard cycle as opposed to the N-stop cycle-12.6 ± 3.3 days vs. 12.1 ± 5.6 days-but not significantly so. This means that the average length of stimulation without GnRH-a in the N-stop protocol was 7.1 days, thus 33/36 (91.6%) of our patients did not have a prema- ture LH surge before hCG for an average of 1 week without Nafarelin. Luteinizing hormone levels on the day of hCG administration were all less than 6 IU/L except for the three cancelled cycles. There was no difference between the duration of stimulation in the cancelled and noncancelled patients.
When analyzed by group analysis, there were no significant differences between the two protocols in terms of average number of ampoules of hMG per cycle used (45 ± 12 vs. 43 ± 12), peak serum estradiol (1332 ± 800 vs. 1189 ± 770 pg/ml), or number of oocytes aspirated per cycle (5.9 ± 4 vs. 7.2 ± 5.3). Similarly, a trend towards better cleavage rates and embryo morphology was recorded in the N-stop cycle as opposed to the standard cycle when the group was taken as a whole (50 ± 28% vs. 60 ± 31% and 2.19 ± 0.6 vs. 1.8 ± 0.53, respectively), but this trend was not statistically significant. The number of oocytes (in both cycles) obtained was loosely correlated (inversely) with basal FSH levels, but not significantly so (Pearson coefficient of correlation r = −0.52).
When data were analyzed by paired analysis (same patient's performance in the standard vs. N-stop cycle), it became apparent that the mean change in response for some parameters, for each patient as an individual was improved (Table I ). The number of total ampoules of hMG administered per cycle per patient was only slightly less in the N-stop cycle as opposed to the standard cycle. The level of peak estradiol was increased by a mean of 16.9% per patient in the N-stop cycle as opposed to the standard cycle, but this was not statistically significant. The mean change in the number of oocytes per patient was increased by 28%, (which may be expressed as the equivalent of 1.6 more oocytes per cycle) in the N-stop cycle, this change did not reach statistical significance ( p = 0.08, paired t test). There was a clear positive paired correlation between the number of oocytes obtained in the Standard as opposed to the N-stop cycle (Pearson correlation coefficient = 0.69). The mean change in embryo cleavage was increased by 27.9% per case in the N-stop cycle, this was statistically significant ( p = 0.03), and can also be expressed as a mean increase of available embryos of 0.8 embryo per patient. Morphology was also significantly improvedthe mean change in morphology score of the replaced embryos for each individual patient was improved by 22% ( p = 0.02, paired t test). This can also be expressed as an improvement of mean embryo morphology of 0.36 points per patient. (scale of 1.0-4.0). Specifically, mean embryo morphology was improved in 27 patients (75%), unchanged in 3 (8.3%), and worsened in 6 patients (16%; Fig. 1 ).
The efficacy of gonadotropins was improved by the N-stop protocol, as expressed by an increase in the mean oocyte-obtained per ampoule-hMGadministered ratio of 32.5% ( p = 0.04, paired t test). A positive paired correlation of 0.7 was noted for this variable, reflecting the obvious improvement in oocyte retrieval despite lower gonadotropin dosage. This can also be expressed as a mean increase of 1.1 oocytes per N-stop cycle if the same amount of gonadotropin was administered, or a mean of seven ampoules less administered per cycle to achieve the same amount of oocytes in the same patient in a N-stop cycle. The peak estradiol level in the cycle was analyzed in the same fashion. The mean peak-estradiol per ampoule-hMG-administered ratio in the N-stop cycle as compared with the standard cycle was increased by 26.8% (not statistically significant, p = 0.057). This can also be expressed as a mean decrease of 3 ampoules per N-stop cycle to achieve the same peak estradiol level.
Clinical pregnancy was achieved in seven of 36 Nstop cycles (35 embryo transfers) as opposed to no pregnancy in the standard cycle, PR = 20% (7/35). Five of these pregnancies resulted in singleton term deliveries with normal neonates, live delivery rate = 14.3% (5/35). All pregnancies were achieved in those patients whose embryo morphology score was improved (5/7) or unchanged (2/7) in the N-stop cycle.
DISCUSSION
GnRH agonist administration is virtually universal in modern IVF stimulation protocols, enabling ovarian stimulation without interference by endogenous pituitary gonadotropin secretion. The addition of these medications has greatly increased ART success rates and as such are associated with extremely low cancellation rates and practically no side effects. Notwithstanding these facts, evidence has accumulated in recent years that GnRH agonists have extrapituitary effects, especially at various sites in the genital tract, in a number of mammalian species (12, 13) .
GnRH receptors, GnRH receptor mRNA, and receptor binding have been found in endometrial, myometrial, endosalpingeal (14) , and placental cells (15) . GnRH has been found to have receptors in ovarian granulosa-both follicular phase and luteal cells (16, 17) -and theca cells, and in fact have been found in oocytes (18) . GnRH production in endometrial cells may have an important role in implantation and in the endometrial-embryonic "cross-talk" (14, 19) .
The physiology of such receptors is still enigmaticalthough, as the systemic levels of GnRH are very low, it is more than likely that GnRH (or GnRH-like peptides) produced locally have a direct or indirect paracrine/autocrine role in regulation of ovarian function (20) (21) (22) (23) . In vitro studies in mice (5) demonstrated that fertilization rates in the presence of low concentrations of GnRH-a were enhanced, demonstrating a direct effect of GnRH-a on oocytes in an in vitro culture system.
The direct effect of GnRH and its agonists on ovarian steroidogenesis is especially important in the context of ART for poor-responder patients. Some studies failed to show a clear-cut effect of GnRH-a on steroid production in vitro (24, 25) where others reported a stimulatory effect at low concentrations of GnRH (3). Gaetje (4) found a dose dependent inhibition of FSH-induced granulosa cell estradiol production by Decapeptyl (D-triptorelin) as opposed to control cultures. Parinaud and colleagues (3) found that GnRH-a (Buserelin) added to luteal phase granulosa cell cultures inhibited LH induced progesterone synthesis. These studies convincingly argue for an inhibitory, negative direct effect of GnRH-a on ovarian folliculogenesis or follicular function, in patients with normal (non-PCOS) ovaries.
Numerous studies have investigated ways to overcome or bypass the direct GnRH-a effect on the ovary. Some authors have tried to reduce GnRH-a doses or to stop its administration during exogenous gonadotropin stimulation to improve ovarian responsiveness, although the results have been contradictory. Higher estradiol levels were achieved with lower doses of gonadotropins, increasing cost-effectiveness, but PR's were unchanged (26, 27) . Several groups have tried discontinuation protocols with varying success. Hazout (9) utilized a 7-day triptorelin protocol starting on Cycle day 2. When compared with the classic triptorelin 3.75 mg depot form, the discontinuation protocol yielded more embryos per cycle despite markedly decreased hMG requirements, and the cancellation rate was quite low at 2.3%. Pantos and colleagues (28) described their experience with discontinuing subcutaneous Buserelin 0.5 mg/d after 10 days starting in the mid-luteal phase. There were no differences in estradiol levels, hMG dose, or oocytes recovered, although the PR in the discontinuation group was almost twice that of the standard protocol (35.2% vs. 19.4%). There were no cancellations in the discontinuation group, despite up to 12 days without GnRH-a. Sungurtekin and Jansen (29) similarly showed that LH levels were suppressed for 11 days after discontinuation of leuprolide acetate. Fujii et al. (30) also studied two groups of patients in a discontinuous GnRH-a protocol, initiating down-regulation in the mid-luteal phase and discontinuing the analogue at Cycle day 7. Interestingly, these authors found that in the discontinuous protocol, more hMG was needed, but less oocytes were fertilized and the cancellation rate was very high (35%). These patients were selected at random from the general IVF population and were not identified as being "poor responders." Faber et al. (31) stopped administration of leuprolide at the onset of menses, in conjunction with high dose gonadotropin therapy. Pregnancy rates were improved in this protocol in a group of 182 low responders. Only 1.2% of cycles were cancelled (1/80) because of premature elevation of LH. Another study (32) examined the positive relationship between delay of hMG initiation after depot form GnRH-a and ovarian response and pregnancy rates, this seems to indicate that initiation of gonadotropin stimulation in the presence of reduced concentrations of GnRH-a improves ovarian response and implanation rates. Recently, Dirnfeld and associates examined the effect of a GnRH-a midluteal "stop" protocol in a randomized study (33) . One cycle of 40 in the study group was cancelled because of premature LH elevation. A trend towards more oocytes obtained in the study group was found only in those patients previously designated as normal-FSH poor responders; in the general IVF population, no significant differences were demonstrated between the "stop" and the conventional protocol. Conversely, Pinkas and coworkers demonstrated a greater yield of oocytes and subsequently more available embryos for transfer with their "stop" protocol, with no premature LH surges (34) .
Our results demonstrate that discontinuation of daily administered GnRH-a in mid-stimulation will not significantly increase cancellation rates due to premature LH surges. This is probably true in a population of poor responders only, and cannot be necessarily extrapolated to include the general IVF population, as Fujii et al. (30) found. Our protocol also differed from others in that it continued the Nafarelin through menses and initiation of stimulation, until the fifth stimulation day. This ensured that the mean treatment period with gonadotropins without GnRH-a coverage was not more than 7 days, and this might be one factor responsible for the low cancellation rate.
Embryo morphology was significantly improved in the N-stop cycle, with each patient acting as her own control. Good quality embryos are significantly associated with improved ongoing pregnancy rates; in fact, embryo quality was found to have a more profound impact on implantation rates in IVF than did age (36) (37) (38) . As more embryos were available for replacement (mean 0.8 more embryos per patient-2.6 to 3.4 embryos per transfer) and the embryo morphology was improved (by a mean of 0.36 points per patient) in the N-stop cycle, the net result was replacement of one more embryo per patient with a mean morphology score improved by one point. Improved morphology, if all other factors are comparable, is most likely due to improved oocyte quality, which might be attributable to the change in stimulation protocol. Improved oocyte quality and increased fertilization/cleavage rates may also be attributed to lower in vitro levels of GnRH-a in the follicular fluid in the study cycle as opposed to the standard cycle, in accordance with in vitro findings by Yang et al. (5) . This finding differs from that found by Smitz et al. (39) who found that cessation of GnRH-a resulted in poorer quality of supernumerary embryos than did standard protocols. One possible explanation for these differing results might be elevated pre-hCG LH levels in patients in the Smitz study.
Ovarian response was also augmented in the N-stop cycle, as opposed to the previous standard cycle. This was deduced by noting a significantly improved ratio of oocytes-obtained per ampoule-hMGadministered. After optimally controlling for other variables-especially by comparing the same patient's response with the same drugs in a slightly different protocol-this statistically significant improvement can be interpreted as an increased efficacy of gonadotropins at the ovarian-follicular level. Efficacy of gonadotropins in this context, may be expressed as an improved response in terms of estradiol production and an improved oocyte yield, per unit exogenous gonadotropin expended. Improved oocyte yield should be expressed as both more and better oocytes obtained. Our results appear to support the surmise that discontinuation of the GnRH-a during gonadotropin stimulation rescinds an inhibitory effect of the GnRH-a on the ovary, enabling an improved ovarian response. This improvement includes both a more efficacious gonadotropin effect on the ovary, allowing growth of more follicles, and a follicular environment that supports the development of better quality oocytes. It is possible that the discontinuation of GnRH-a also had a beneficial influence on implantation, as GnRH has been found to play a role in embryo-endometrial communication (40). Although the case-control design of this study is not randomized, comparing the same patient's performance in consecutive cycles that differ only in one variable, has the advantage of optimal controlling for differences that might be expressed in randomized patient groups, thereby confounding results. Larger studies could increase the significance of our findings. We believe that patients with poor response in both quantity and especially quality of oocytes could benefit from discontinuing GnRH-a during stimulation, without significantly raising cancellation rates. Further study is underway in in vitro models in an effort to define the direct effect of GnRH-a on granulosa cells and oocytes, to better discern the different patterns of response in different patient groups. 
